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Endogenous and exogenous galectin-3 promote the adhesion of tumor cells with 1 
low expression of MUC1 to HUVECs through upregulating N-cadherin and 2 
CD44  3 
 4 
ABSTRACT 5 
Tumor cell-endothelial adhesion is one of the key steps in tumor cell haematogenous 6 
dissemination in metastasis and is previously shown to be mediated by interaction of 7 
galectin-3 with the transmembrane mucin protein MUC1. In this study, effect of 8 
exogenous as well as endogenous galectin-3 on adhesion of low MUC1-expressing 9 
human prostate cancer PC-3M cells and non-small cell lung cancer A549 cells to 10 
monolayer of umbilical vein endothelial cells (HUVECs) was investigated. It was 11 
found suppression of endogenous galectin-3 expression reduced tumor cell adhesion 12 
to HUVECs and also decreased cell invasion and migration. Exogenous galectin-3 13 
promoted tumor cell adhesion to HUVECs by entering into cells. Both exogenous and 14 
endogenous galectin-3 upregulated the expression of β-catenin and increased 15 
β-catenin nuclear accumulation, and then upregulated the expression of N-cadherin 16 
and CD44. We deduced that both exogenous as well as endogenous galectin-3 17 
promoted low MUC1-expressing cancer cell adhesion to HUVECs by increasing the 18 
expression of N-cadherin and CD44 via an increase of β-catenin nuclear accumulation. 19 
These results were confirmed further by using β-catenin/TCF transcriptional activity 20 
inhibitor, N-cadherin or CD44 siRNAs. This suggests a new molecular mechanism of 21 
galectin-3-mediated cell adhesion in cancer metastasis.  22 
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INTRODUCTION 1 
Galectin-3 (Gal-3) is a 29-kDa β-galactoside-binding protein and was firstly identified 2 
on murine thioglycollate-elicited peritoneal macrophages.1 Gal-3 is the only member 3 
of chimera type of galectins and is expressed intracellularly and extracellularly by 4 
various cell types.2 It is composed of a carbohydrate recognition domain (CRD) at the 5 
C-terminal and a long repetitive collagen-like sequence at the N-terminal domain 6 
which is sensitive to proteolysis by MMP-2 and MMP-9.3 In addition, Gal-3 is able to 7 
dimerize and polymerize in some specific conditions, such as at high concentration or 8 
the presence of ligands. It is synthesized in the cell cytoplasm and can also be secreted 9 
to the cell surface and extracellular environment to be involved in many biological 10 
events, such as immune regulation, apoptosis, cell adhesion, mRNA splicing and 11 
embryogenesis.  12 
Over the past years, more and more evidence showed that both endogenous and 13 
exogenous Gal-3 involved in angiogenesis, cancer cell adhesion, proliferation and 14 
metastatic spreading. Endogenous Gal-3 is upregulated in various cancer cells, such 15 
as breast cancer, colon cancer, gastric cancer, lung cancer, liver cancer, etc,4-6 and 16 
plays an important role in cell invasion, apoptosis, transcription, mRNA splicing and 17 
cell growth. An early research showed that cytoplasmic Gal-3 inhibited apoptosis by 18 
binding to B-cell lymphoma 2 (Bcl-2).7 Endogenous Gal-3 was also shown to increase 19 
nuclear β-catenin accumulation by regulation of GSK-3β activity, and promote colon 20 
cancer cells progression.8 The concentrations of Gal-3 in the serum from patients with 21 
breast, lung, gastrointestinal, head and neck or ovarian cancer, melanoma and 22 
pancreatic cancer were higher than that in serum from healthy individuals. The level 23 
of circulating galectin-3 was found apparently higher in the serum of cancer patients 24 
those with metastasis.9 Higher circulating Gal-3 level is considered a potential 25 
biomarker for colorectal cancer metastasis.10 Extracellular Gal-3 is associated with 26 
tumor cell dissemination, survival, cancer-matrix adhesion, cancer-endothelial 27 
adhesion, angiogenesis and cell growth through interaction with cell surface glycans 28 
such as MUC111,12 and integrins.7,13  29 
Cell adhesion molecules (CAMs) are a group of transmembrane proteins, each of 30 
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which is composed of extracellular, transmembrane and cytoplasmic domains. CAMs 1 
are divided into five groups including integrins, cadherins, selectins and lymphocyte 2 
homing receptors and the immunoglobulin superfamily (Ig-SF). Exogenous Gal-3 was 3 
reported to regulate cell adhesion through interaction with N-cadherin, GM1 4 
ganglioside, Mgat5-modified N-glycans, fibronectins, laminin, collagen IV and 5 
elastin.14-18,4 Moreover, Gal-3 was demonstrated to promote polarization of the 6 
transmembrane mucin protein MUC1 by binding to the carbohydrate TF 7 
(Galβ1,3galNAcα-) antigen. MUC1 polarization by Gal-3 exposes the cadherin 8 
molecules, leading to increase cancer cell adhesion to vascular endothelial cells.11,19 9 
However, effect of extracellular Gal-3 on adhesion of tumor cells with low expression 10 
of MUC1 to vascular cells is unknown.   11 
In the present study, we found that endogenous Gal-3 promoted adhesion of tumor 12 
cells to HUVECs through upregulation of the expression of CAMs, N-cadherin and 13 
CD44, an effect was found to be partly mediated by nuclear accumulation of β-catenin 14 
in human non-small cell lung cancer A549 cells. Exogenous introduction of 15 
recombinant Gal-3 was also seen to enter into low Gal-3-experssion human prostate 16 
cancer PC-3M cells and high Gal-3-expression A549 cells and increase cell β-catenin 17 
nucleus accumulation and cell adhesion to HUVECs. 18 
 19 
MATERIALS AND METHODS  20 
Materials 21 
RPMI-1640 medium, Ham's F-12K (Kaighn's) medium, fetal bovine serum and 22 
L-glutamine were purchased from GINCO BRL (Grand Island, NY, USA). 23 
Endothelial cell medium (ECM) were purchased from ScienCell (San Diego, 24 
California, USA). Monoclonal antibodies (mAb) against human Gal-3, MMP-2, 25 
MMP-9 and β-catenin were purchased from Cell Signaling Technology (Boston, MA, 26 
USA). Rabbit Polyclonal antibodies against MUC1, CD44 and N-cadherin were from 27 
Proteintech Group, Inc (Chicago, IL, USA). Recombinant full-length human 28 
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galectin-3 was from Abcam (Cambridge, UK). ICG-001 was from Aladdin Aladdin 1 
Reagent Company (Shanghai, China). ECL reagent, Membrane and Cytosol Protein 2 
Extraction Kit and Immunol Fluorence Staining Kit was from Beyotime (Shanghai, 3 
China). Subcellular Structure of Cytoplasm and Cell Nucleus Extraction Kit was from 4 
Boster Biological Technology (Wuhan, China). Bovine serum albumin (BSA), 5 
Vybrant DiO Cell labelling Solutions, radio immunoprecipitation assay (RIPA) lysis 6 
buffer and phenylmethane sulfonyl fluoride (PMSF, 100 mmol/L) were purchased 7 
from Solarbio (Beijing, China). Gal-3 and N-cadherin siRNAs were purchased from 8 
GenePharma Corporation (Shanghai, China). The coding strand targeting by Gal-3 9 
siRNA duplex was 5’-CAC GCT TCA ATG AGA ACA ACA-3’ and N-cadherin 10 
siRNA duplex was 5’-CTA ACA GGG AGT CAT ATG GTG GAGC-3’. The control 11 
siRNA was 5’- TTC TCC GAA CGT GCT GTC TTT-3’. CD44 siRNA was purchased 12 
from Santa Cruz Biotechnology (CA, USA). Lipofectamine 2000 Reagent, TRIzol 13 
Reagent and Opti-MEM Culture Medium were purchased from Invitrogen (Carlsbad, 14 
California, USA). Both MUC1 mRNA and β-actin mRNA were synthesized by 15 
GenePharma Corporation (Shanghai, China). qPCR RT Kit and SYBR Green 16 
Realtime PCR Master Mix were purchased from TOYOBO (Japan). XenoLight 17 
D-Luciferin Potassium Salt was purchased from Caliper Life Sciences 18 
(Hopkinton, MA, USA). Culture dish, 6-well plates, 24-well plates and 24-well 19 
transwell chambers with 8.0 μm polycarbonated filters were purchased from Corning 20 
(NY, USA). Matrigel was purchased from Becton Dickinson and Company (Franklin, 21 
USA). 22 
Cell lines 23 
Human prostate carcinoma cell line (PC-3M) was obtained from American Type 24 
Tissue Culture (Rockefeller, Maryland, USA). Human non-small cell lung cancer cell 25 
line (A549) and Human umbilical vein endothelial cells (HUVECs) were obtained 26 
from Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China. 27 
Luciferase-labeled A549 cells (A549-Luc cells) which were kindly provided by 28 
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Caliper Life Sciences, Inc (Hopkinton, MA, USA) were cultured in Ham's F-12K 1 
(Kaighn's) medium supplemented with 10% fetal bovine serum. A549 cells and 2 
PC-3M cells were cultured in RPMI 1640 medium supplemented with 10% fetal 3 
bovine serum. HUVECs were cultured in ECM medium supplemented with 10% fetal 4 
bovine serum. In addition, 100 U/ml streptomycin / penicillin were added to RPMI 5 
1640 medium and ECM medium. All of the cells were cultured in incubator at 37°C, 6 
5% CO2. 7 
Gal-3 small interfering RNA (siRNA) transfection 8 
A549 cells (2×105) seeded into 6-well plates cultured to 60% confluence before 9 
transfection. Transfection with 8 μl control, Gal-3, CD44 or N-cadherin siRNA duplex 10 
(25 μmol/L) was performed using 5 μl Lipofectamine 2000 Reagent in 500 μl 11 
Opti-MEM Culture Medium. After incubating 8 h, change Opti-MEM Culture 12 
Medium to RPMI 1640 medium supplemented with 10% fetal bovine serum. Then 13 
cells were incubated at 37°C for 24 h. The efficiency of galectin-3 knockdown was 14 
assessed by Western blot analysis of cellular lysates. 15 
Cancer cell-endothelial adhesion 16 
Cancer cell-endothelial adhesion was performed as previously described.11 Tumor 17 
cells were cultured in 6-well plates and HUVECs was cultured in 24-well plates. 18 
Tumor cells treated with Gal-3, Gal-3 siRNA (siGal-3) transfection or ICG-001 19 
(β-catenin/TCF transcriptional inhibitor). After washed with PBS, tumor cells were 20 
released from the culture plates and labeled with 5 μmol/L DIO fluorescent cell 21 
labeling solution in serum-free RPMI 1640 medium for 30 min at 37°C. After 22 
resuspension, 5×104 cells were applicated to the HUVECs monolayer cultured in 23 
24-well plates for 1 h at 37°C. Then the 24-well plates were gently washed with PBS 24 
to remove free tumor cells and the fluorescently labeled cells remaining on the 25 
endothelial monolayer were counted in ten randomly selected fields of view using 26 
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fluorescent microscope (NIKON Ti-U, Nikon, Japan) with a 10 objective (100 1 
magnifications). 2 
Immunofluorescence staining 3 
A549 and PC-3M cells were seeded into 24-well plates (with coverslips inserted) at 4 
density of 5×104 cells per well. Gal-3 was added to PC-3M and A549 cells after 5 
overnight culture at 37°C. The cells were fixed with ice-cold methanol/glacial acetic 6 
acid (3:1) for 10 min and blocked with 3% bovine serum albumin (BSA) in PBS for 7 
20 min at room temperature. Then cells were incubated with a mouse anti-galectin-3 8 
antibody (1:200) overnight at 4°C and followed by reaction with FITC-conjugated 9 
secondary antibody (1:500) for 2 h at 37°C. Finally, cells were stained with Hoechst 10 
33342 to stain the nuclear, and fluorescence images were taken with fluorescence 11 
microscope (NIKON Ti-U, Nikon, Japan) with a 10 objective (150 magnifications). 12 
Wound scratch assay  13 
A549 cells were seeded into 6-well plates and transfected with siRNA of Gal-3 or 14 
treated by ICG-001. The cell monolayer was scraped in a straight line with a p200 15 
pipette tip and incubated under serum-free conditions. Photographs of the scratch 16 
were taken under an invert microscope at 0 h, 12 h, 24 h, 36 h and 48 h. Photographs 17 
at each time point were taken with Leica DFC420 camera. Gap width analysis was 18 
performed with scaleplate in microscope. Measurements were taken at multiple 19 
defined sites (>6) along the scratch. Each scratch was given an average of all 20 
measurements. Data are derived from three independent experiments. 21 
Formula: 22 
Migration distance = (Gap width at 0 h - Gap width at different time points)/ Gap 23 
width at 0 h 24 
 25 
Cell invasion assay 26 
 27 
A549 cells were seeded into 6-well plates and transfected with siRNA of Gal-3 or 28 
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treated by ICG-001. The cells were released from the culture plates and suspended in 1 
medium without serum before application of 1×106 cells/well to the top side of the 2 
transwells. Medium with serum was added to the bottom chamber as a 3 
chemoattractant. After incubation at 37°C for 24 h, cells remained in the top chambers 4 
(non-invasive) were removed together with the medium. The invaded cells in the 5 
bottom chamber were counted under a microscope with a 20 objective (200 6 
magnifications). 7 
Western blot analysis 8 
A549 cells and PC-3M cells were lysed in a RIPA lysis buffer, cytoplasmic extraction 9 
reagent and nucleus extraction reagent using Subcellular Structure Cytoplasmic and 10 
Nucleus Extraction Kit or membrane extraction reagent and cytoplasmic extraction 11 
using Membrane and Cytosol Protein Extraction Kit. Proteins were separated by 10% 12 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After 13 
electrophoresis, the proteins were electrotransferred to PVDF membranes and then 14 
blocked with 5% non-fat milk for 4 h. The membranes were then incubated with a 15 
primary antibody against galectin-3, β-catenin, MMP-2, MMP-9, CD44, N-cadherin, 16 
PCNA and β-actin at 4°C for 12 h. After three washes in TBST, the membranes were 17 
incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room 18 
temperature and were visualized by ECL reagent through Chemidoc XRS imaging 19 
system (Bio-Rad, Hercules, California, USA).  20 
Quantitative real-time PCR 21 
Total RNA was extracted from the cell pellets using TRIzol Reagent following the 22 
manufacturer’s instructions. The RNA concentration was measured by UV absorption 23 
at 260 and 280nm. The A260/A280 ratio was calculated to assess RNA quality and 24 
purity. First-strand cDNA was produced from total RNA by using a qPCR RT Kit, 25 
according to manufacturer’s instructions. Samples were cycled for 30 s at 95°C, 30 s 26 
at 59°C and 30 s for 72°C for 40 cycles. QRT-PCR of the MUC1 mRNA and β-actin 27 
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mRNA as internal control was performed on a LightCycler 480 II real-time PCR 1 
system (Roche, Basel, Switzerland), using the SYBR-Green Chemistry.  2 
Metastasis animal model and bioluminescent imaging 3 
Six-week-old female Balb/c athymic nude mice were maintained and used in 4 
accordance with the animal care protocol approved by Shandong University. Ten 5 
experimental animals were divided randomly into two groups. 5 animals / group were 6 
injected with A549-Luc cells which were transfected with siGal-3 or control siRNA 7 
via tail vein. The animals were maintained under standard conditions and observed 8 
daily. The mice were anesthetized and the fluorescence signal was monitored using 9 
the IVIS Kinetic in vivo imaging system (Caliper Life Sciences, Hopkinton, MA, 10 
USA) in nine minutes after injecting D-luciferin potassium salt intraperitoneally every 11 
10 days for up to 40 days. All mice were sacrificed and dissected for examining 12 
metastatic foci by light microscopy at day 40. 13 
 14 
Statistical analysis 15 
All quantitative data are expressed as mean ± SD. Statistical comparisons were 16 
performed by one-way analysis of variance. A P-value < 0.05 was considered 17 
statistically significant. Statistical analysis was performed using the SPSS/Win 13.0 18 
software. 19 
 20 
RESULTS  21 
Either endogenous or exogenous Gal-3 increased A549 or PC-3M cells adhesion 22 
to HUVECs 23 
Two tumor cell lines, A549 cells which has high expression of endogenous Gal-320 or 24 
PC-3M cells which has hardly expression of endogenous Gal-321 was chose to 25 
investigate the effects of endogenous or exogenous Gal-3 on tumor cell-HUVEC 26 
adhesion. The expression level of Gal-3 in A549 cells or PC-3M cells was confirmed 27 
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in Figure 1A. To detect the effect of endogenous Gal-3 on the adhesion of A549 cells 1 
to HUVECs, Gal-3 siRNA was used to down-regulate the expression of Gal-3. A549 2 
cells transfected with Gal-3 siRNA (siGal-3) showed significantly less adhesion 3 
(reduction rate of 41.2%, P < 0.01) to HUVECs compared with A549 cells treated 4 
with control siRNA (Fig. 1E).  5 
It was reported previously that exogenous Gal-3 at concentrations similar to that 6 
seen in cancer patients promoted cancer cell adhesion to HUVECs by interaction with 7 
MUC1 expressed on the membrane of cancer cells.11,19 However, in the present study, 8 
we want to observe the effects of exogenous Gal-3 on the adhesion of HUVECs to 9 
cancer cells with low expression of MUC1. A549 and PC-3M cells were reported to 10 
have low MUC1 expression,22,23 which was confirmed in Figure B using HT-29 cells 11 
as positive control cell lines with high expression of MUC1. What’s more, MUC1 12 
mRNA expression in A549 and PC-3M cells was also lower than that in HT-29 cells 13 
(Fig. 1C). In addition, the recombinant Gal-3 could not affect the expression of 14 
MUC1 in these two cell lines (Fig. 1D). We examined the adhesion of A549 or 15 
PC-3M cells to HUVECs by incubation with different concentration of recombinant 16 
Gal-3 for 8 h. Results showed that 0.1, 0.5, 1 μg/ml Gal-3 significantly increased 17 
PC-3M cells adhesion to HUVECs by 12.6%, 33.7% and 56%, and increased A549 18 
cell adhesion to HUVECs by 19.6%, 39.4% and 55.1% compared with control cells 19 
(Fig. 1F and 1G). These results indicated exogenous Gal-3 may promote tumor 20 
cell-HUVEC adhesion also through a MUC1-independent mechanism. 21 
 22 
Endogenous Gal-3 promoted A549 cells-HUVECs adhesion by upregulating 23 
CD44 and N-cadherin expression  24 
Previous studies showed that endogenous Gal-3 could bind to β-catenin and regulate 25 
accumulation of β-catenin in nucleus.8 In this study, downregulation of Gal-3 26 
expression in A549 cells was shown to be associated with reduction of cell adhesion 27 
and decrease of the accumulation of β-catenin in nucleus (Fig. 2A).  28 
To investigate whether β-catenin was involved in A549 cells adhesion to HUVECs, 29 
ICG-001, a small-molecule inhibitor to specially block β-catenin/TCF transcriptional 30 
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activity,24 was introduced into the adhesion system. It was found that pretreatment of 1 
A549 cells with 5 μmol/L and 10 μmol/L ICG-001 resulted in reduction of A549 cells 2 
adhesion to HUVECs with reduction rate of 11.4% (P < 0.05) and 42.1% (P < 0.01), 3 
respectively compared with untreated A549 cells (Fig. 2B). 4 
To further determine whether the effect of endogenous Gal-3 on cancer 5 
cell-endothelial adhesion was involved in β-catenin/TCF transcriptional activity, A549 6 
cells were incubated with ICG-001 after being transfected with control siRNA or 7 
siGal-3. As shown in Fig. 2C, in the presence of ICG-001 (10 μmol/L), control siRNA 8 
and siGal-3 treatment induced similar effect on reduction (51.2%, P < 0.01 and 49.3%, 9 
P < 0.01) of A549 cells adhesion to HUVECs compared to blank control group. These 10 
data indicated that the involvement of endogenous Gal-3 in the adhesion of A549 cells 11 
to HUVECs was depending on β-catenin/TCF transcriptional activity. 12 
As many CAMs are involved in mediating cancer cell-endothelial adhesion and 13 
CD44 was regulated by β-catenin,25 we speculated that endogenous Gal-3 might 14 
promote A549 cells adhesion to HUVECs through regulating the expression of 15 
N-cadherin and CD44 via β-catenin/TCF. High expression of N-cadherin showed in 16 
both HUVECs and A549 cells (Fig. 3B) which suggested that N-cadherin might be a 17 
key CAM involving in A549 cell-HUVEC adhesion. As shown in Fig. 3A, 18 
downregulation of cell Gal-3 expression inhibited the expression of N-cadherin and 19 
CD44 in A549 cells. After treatment with ICG-001 (β-catenin/TCF transcriptional 20 
inhibitor), the expression of N-cadherin in A549 cells was decreased in a 21 
concentration-dependent manner, while the expression of CD44 showed no significant 22 
change which suggested that CD44 is also regulated by other ways (Fig. 3C). 23 
However, in the presence of 10 μmol/L ICG-001, Gal-3 downregulation did not 24 
decrease the expression of N-cadherin and CD44 (Fig. 3D). These indicated that the 25 
decreased expressions of N-cadherin and CD44 induced by Gal-3 downregulation 26 
were dependent on the presence of β-catenin. 27 
  28 
Recombinant Gal-3 promoted tumor cell (low MUC1 expression) adhesion to 29 
HUVECs by entering into cells and upregulating β-catenin expression and 30 
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nuclear accumulation  1 
We next explored the mechanism of exogenous Gal-3 on MUC1-independent cancer 2 
cells adhesion to HUVECs. It has been reported that exogenous Gal-3 had the ability 3 
to enter macrophages via endocytosis.26 Thus, we speculated that introduction of 4 
recombinant Gal-3 to the cells could get into the cells and regulate adhesion of A549 5 
or PC-3M cells (with low MUC1 expression) to HUVECs through the similar ways as 6 
intracellular Gal-3. Firstly, recombinant Gal-3 showed the ability to enter into no 7 
gal-3 expressing PC-3M cells (Fig. 4A). After incubation with recombinant Gal-3, the 8 
expression of Gal-3 in PC-3M cells was rapidly increased in a time-dependent manner 9 
during 2 h, and then decreased gradually within 8 h. After incubation of PC-3M cells 10 
with 0.5, 1 μg/ml recombinant Gal-3 for 8 h, Gal-3 entered into both cytoplasm and 11 
nucleus in dose-dependent manner (Fig. 4B, 4C). Recombinant Gal-3 also showed 12 
ability to enter into A549 cells (with high expression of endogenous Gal-3) after 13 
down-regulating the expression of Gal-3 by RNA interference (siGal-3) (Fig. 5A). 14 
Results showed that Gal-3 could be seen in both cytoplasm and nucleus of A549 cells 15 
in endogenous Gal-3 knockdown cells (Fig. 5B). In order to rule out cell membrane 16 
contamination of Gal-3 expression in cytoplasm, we separated the cell membrane and 17 
cytoplasm using Membrane and Cytosol Protein Extraction Kit. The result showed the 18 
expression of Gal-3 in cytoplasm was significantly increased after incubation of 19 
PC-3M and A549 cells with 1 μg/ml recombinant Gal-3 for 2 h (Fig. 5C). So, the 20 
present data confirmed that exogenous recombinant Gal-3 had the ability to enter the 21 
cytoplasm and nucleus of tumor cells with low level of endogenous Gal-3. 22 
Simultaneously, the entrance of Gal-3 in PC-3M cells was accompanied with the 23 
increased expression of β-catenin in nucleus which indicated its nucleus accumulation 24 
(Fig. 4C). Moreover, the expression of β-catenin in both cytoplasm and nucleus in 25 
A549 cells transfected with siGal-3 also decreased, while it was increased in the 26 
presence of recombinant Gal-3 (Fig. 5B).  27 
After being transfected with siGal-3, the adhesion of A549 cells to HUVECs was 28 
significantly increased by introduction of 1 μg/ml recombinant Gal-3 for 8 h (Fig. 6A). 29 
But this effect did not occur in the presence of 10 μmol/L ICG-001 (Fig. 6B). 30 
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Similarly, the presence of 10 μmol/L ICG-001 reduced recombinant Gal-3 (1 μg/ml, 8 1 
h)-mediated increase of PC-3M cell adhesion to HUVECs (Fig. 6C). 2 
Taken together, these results indicated that exogenous Gal-3 could promote the 3 
adhesion to HUVECs of tumor cells with low MUC1-expression by upregulating 4 
β-catenin and its nuclear translocation.  5 
        6 
N-cadherin and CD44 were involved in promoting tumor cells adhesion to 7 
HUVECs induced by exogenous Gal-3  8 
After treatment of PC-3M cells with 1 μg/ml recombinant Gal-3 for 0 h, 1 h, 2 h, 4 h 9 
and 8 h, the expression of N-cadherin and CD44 in PC-3M cells showed a 10 
time-dependent increase (Fig. 4B). After treatment with 0.5, 1 μg/ml recombinant 11 
Gal-3 for 8 h, the expressions of N-cadherin and CD44 in PC-3M cells or A549 cells 12 
were significantly increased (Fig. 7A and 7B). Moreover, after A549 cells transfected 13 
with Gal-3 siRNA, the endogenous expression of N-cadherin and CD44 decreased in 14 
comparison with that in control siRNA cells, while increased after incubation with 15 
recombinant Gal-3 for 8 h (Fig. 7C). To further investigate the relationship between 16 
increased expression of N-cadherin and CD44 induced by recombinant Gal-3 and 17 
β-catenin, 10 μmol/L ICG-001 was used to inhibit the β-catenin/TCF transcriptional 18 
activity.  19 
However, when A549 cells were exposed to ICG-001 (10 μmol/L), the expression 20 
of N-cadherin significantly decreased while the expression of CD44 has no markedly 21 
difference. And recombination Gal-3 couldn’t alter the expression of these two CAMs 22 
in the presence of ICG-001 (Fig. 7D). These results suggested that exogenous Gal-3 23 
could upregulate the expression of N-cadherin and CD44 in both A549 cells and 24 
PC-3M cells in the presence of β-catenin.  25 
To gain further insight into the role of N-cadherin and CD44 in regulating adhesion 26 
of tumor cells to HUVECs, siRNA to N-cadherin or CD44 in A549 cells was 27 
conducted before performance of cell adhesion to HUVECs. It was found that 28 
suppression of N-cadherin or CD44 by RNA interference resulted in reduction of 29 
adhesion of A549 cells to HUVECs. After treatment with 1 μg/ml recombinant Gal-3 30 
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for 8 h, adhesion of A549 cells transfected with siCD44 or siN-cadherin to HUVECs 1 
was significantly increased, accompanying with an increase of CD44 and N-cadherin 2 
expression (Fig. 8A, 8B, 8C). Interestingly, suppression of N-cadherin expression 3 
induced more reduction of A549 cells adhesion to HUVECs (53.7%) than suppression 4 
of CD44 expression (36.3%). These results indicate that N-cadherin and CD44 may 5 
both play an essential role in Gal-3-mediated tumor cell-HUVEC adhesion, but 6 
N-cadherin may make more contribution than CD44.  7 
 8 
Endogenous Gal-3 promoted migration and invasion of A549 cells also depending 9 
on β-catenin/TCF transcriptional activity 10 
In the wound scratch assay, suppression of Gal-3 expression by RNA interference in 11 
A549 cells resulted in slower closure of the gaps than that in blank group or control 12 
siRNA group for 0 h, 12 h, 24 h, 36 h and 48 h. In the presence of ICG-001 (10 13 
μmol/L), the A549 cell migration was significantly inhibited at 24 h, 36 h and 48 h in 14 
comparison to blank group. Moreover, co-presence of siGal-3 and ICG-001 almost 15 
completely abolished the ability of A549 cell migration (Fig. 9A).        16 
In the invasion assay, the number of invasive A549 cells through matrigel was 17 
decreased significantly by suppression of Gal-3 expression or ICG-001 in compared 18 
with control siRNA or blank group. Co-presence of siGal-3 and ICG-001 dramatically 19 
inhibited the invasion of A549 cells (Fig. 9B). Moreover, we also observed that 20 
suppression of Gal-3 expression decreased the expression of β-catenin in both 21 
cytoplasm and nucleus (Fig. 5B). These results indicate that endogenous Gal-3 22 
promotes the expression of β-catenin in cytoplasm and its nucleus accumulation, 23 
which may play a crucial role in A549 cells migration and invasion. Moreover, the 24 
expression of MMP-2 and MMP-9 in A549 cells was inhibited by the presence of 25 
ICG-001 in a concentration-dependent manner, indicating that both MMP-2 and 26 
MMP-9 may contribute to the migration and invasion ability of A549 cells induced by 27 
Gal-3/β-catenin pathway (Fig. 9C).  28 
 29 
Downregulation of galectin-3 expression inhibited the metastasis of A549 cells in 30 
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vivo 1 
To explore the effects of Gal-3 in tumor metastasis in vivo, 10 nude mice developed 2 
metastasis after injection of A549-Luc cells which were transfected with siGal-3 or 3 
control siRNA via tail vein. The lung metastasis of A549-Luc cells in nude mice at 4 
different time points was observed using in vivo imaging system. At day 10, obvious 5 
metastatic foci in the lungs appeared in all mice injected with A459-Luc cells by 6 
luciferase image, while weak foci showed in only one mouse injected with A549-Luc 7 
cells transfected with siGal-3 (Fig. 10A). At either day 20 or day 40, the luminescence 8 
intensity of metastatic foci in the lungs in mice injected with A459-Luc cells 9 
transfected with siGal-3 were significantly less than that in mice injected with 10 
A549-Luc cells (Fig. 10B and 10C). The macroscopic appearance of lungs at 40d in 11 
two mice groups also showed the same results as luminescence intensity (Fig. 10D).. 12 
These results indicated that pretreatment of A549 cells with siGal-3 transfection 13 
resulted in an obvious inhibition on the pulmonary metastasis of A549 cells. 14 
           15 
DISCUSSION  16 
Gal-3 is a β-galactoside-binding protein that located inside and outside cells, and is 17 
widely expressed in various tissues. Gal-3 interacts with glycoproteins expressed on 18 
cell surface through its CRD. Gal-3 can bind to β-galactosides present in N-glycans 19 
and O-glycans.27 Thus, Gal-3 could interact with the glycoprotein MUC1 and EGFR, 20 
then regulated MUC1 and EGFR cellular distribution and activated EGFR 21 
downstream pathways in pancreatic cancer cells.28 Exogenous Gal-3 was shown to 22 
promote tumor cell homotypic aggregation and adhesion to HUVECs and increase 23 
EGFR dimerization and activation29 by interaction with O-linked glycans on 24 
MUC1.12,19,30 In this study, exogenous and endogenous galectin-3 showed regulation 25 
on adhesion of tumor cells through MUC1-independent mechanisms.  26 
Firstly, we found that suppression of endogenous Gal-3 by siGal-3 in A549 cells 27 
decreased cell adhesion to HUVECs, an effect that is associated with downregulation 28 
of the expressions of β-catenin and two CAMs, N-cadherin and CD44. Adhesion of 29 
A549 cells to HUVECs was seen to be significantly decreased, and the expression of 30 
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N-cadherin was decreased while the expression of CD44 was not affected in the 1 
presence of β-catenin/TCF-mediated transcription inhibitor ICG-001. This indicates 2 
that β-catenin/TCF-mediated transcriptional activity was closely associated with A549 3 
cell adhesion to HUVECs and the expression of N-cadherin. The presence of ICG-001 4 
showed to abolish Gal-3-mediated increase of A549 adhesion to HUVEC. We 5 
therefore deduce that endogenous Gal-3 promotes A549 cells adhesion to HUVECs 6 
through upregulation of N-cadherin and CD44 via β-catenin/TCF transcription.  7 
The Wnt/β-catenin signaling pathway plays an essential role in homeostasis, 8 
organogenesis and cancer progression. In the absence of Wnt stimuli, β-catenin is 9 
degraded by the complex that contains axin, adenomatous polyposis coli (APC) and 10 
glycogen synthase kinase 3β (GSK-3β). Aberrant activation of the Wnt/β-catenin 11 
pathway can increase β-catenin accumulation in nucleus, leading to activation of the 12 
transcription of Wnt-target genes including cyclin D1, c-Myc.31 The expression of 13 
N-cadherin was upregulated in many tumors, such as prostate cancer, breast cancer, 14 
gastric cancer, colon cancer, pancreatic cancer, esophagus cancer and melanoma 15 
cancer.32-38 In addition, expression of N-cadherin enhances the movement of 16 
HCT-8/E11 colon cancer cells39,40 and was involved in stromal-mesenchymal cell 17 
adhesion.41 In the present study, the high expression of N-cadherin in HUVECs and 18 
A549 cells demonstrated that N-cadherin might be a key CAM to mediate the 19 
adhesion of these two cells. N-cadherin also showed to increase breast cancer 20 
adhesion to endothelial cells and enhance tumor cell ability to enter and exit the blood 21 
vessel.42 N-cadherin was also reported to increase expression of MMP-9 by activating 22 
MEK/MAPK pathway, eventually promote cancer metastasis and invasion.43 It was 23 
previously reported that N-cadherin was upregulated in epithelial-mesenchymal 24 
transition (EMT)36,44 which could be induced by activated β-catenin/LEF-1 signaling 25 
pathway directly.45 However, the transcriptional mechanism of N-cadherin remains 26 
unclear. In this study, Gal-3 expression suppression decreased β-catenin expression 27 
both in cytoplasm and in nucleus, indicating that endogenous Gal-3 promoted nuclear 28 
accumulation of β-catenin. This result was in consistent with early studies.5,46 29 
N-cadherin expression was downregulated by either endogenous Gal-3 suppression or 30 
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exposure to β-catenin/TCF-mediated transcription inhibitor ICG-001 in A549 cells. 1 
Furthermore, endogenous Gal-3 suppression couldn’t downregulate the expression of 2 
N-cadherin in the presence of ICG-001. These results indicate that endogenous Gal-3 3 
upregulates the expression of N-cadherin through promotion of nuclear translocation 4 
of β-catenin.  5 
CD44 is a transmembrane glycoprotein expressed on various cell surfaces47 and 6 
plays a crucial role in regulating adhesion of cell-cell and cell-ECM.48 It promotes 7 
cancer metastasis in many cancers such as breast cancer, gastric cancer, colon cancer, 8 
cervical cancer.49-52 In addition, CD44 has been reported to be a target protein of 9 
Wnt/β-catenin pathway.51,53 In this study, suppression of endogenous Gal-3 expression 10 
was seen to decrease the expression of CD44, which was abolished by ICG-001. 11 
These indicated that the decreased expressions of CD44 induced by Gal-3 suppression 12 
were dependent on the presence of β-catenin. However, the expression of CD44 13 
showed no significant change after treatment with ICG-001 to inhibit the activity of 14 
β-catenin/TCF-mediated transcription, suggesting that there may be other regulatory 15 
mechanism of CD44 transcription which is β-catenin-independent.   16 
In this study, endogenous Gal-3 was observed to promote migration and invasion of 17 
A549 cells depending on β-catenin/TCF transcriptional activity. A combined treatment 18 
of the cells with ICG-001 and siGal-3 produced a synergistic inhibition on A549 cell 19 
invasion and migration. This implied that β-catenin/TCF transcriptional activity 20 
played an important role in Gal-3 induced migration and invasion. Both N-cadherin 21 
and CD44 have been shown previously to promote tumor cell migration and 22 
invasion,32-35,38,50,54 which was in consistence with the results shown in this study. The 23 
discovery that ICG-001 also inhibited the expression of MMP-9 and MMP-2 suggests 24 
that these MMP members may contribute to the migration and invasion of A549 cells 25 
induced by Gal-3/β-catenin pathway.      26 
Previous study had shown that exogenous Gal-3 increased tumor cells adhesion to 27 
HUVECs by binding to MUC1 on cell surface to expose small CAMs.11 In this study, 28 
we observed the effect of recombinant Gal-3 on low MUC1 expressing PC-3M cells 29 
and A549 cells adhesion to HUVECs. Results showed that recombinant Gal-3 also 30 
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increased low MUC1 expressing tumor cells adhesion to HUVECs, suggesting that 1 
other mechanisms being independent on MUC1 existed. An early study reported that 2 
exogenous Gal-3 could be rapidly internalized from the exogenous compartment by 3 
endocytosis in macrophages.26 So we supposed that recombinant Gal-3 could be 4 
internalized in tumor cells via endocytosis. The current results verified this 5 
assumption that Gal-3 entered into the cytoplasm and nucleus of PC-3M cells and 6 
A549 cells by separating cytoplasm with nucleus and cytomembrane with cytoplasm. 7 
Furthermore, results showed that β-catenin was increased in cytoplasm and nucleus of 8 
PC-3M cells and A549 cells after incubation with recombinant Gal-3. Once 9 
β-catenin/TCF-mediated transcription was inhibited by the presence of ICG-001, the 10 
increase of recombinant galectin-3-mediated cell adhesion was reduced. These 11 
indicated that exogenous Gal-3 upregulated cancer cells adhesion to HUVECs also 12 
partly depending on nucleus accumulation of β-catenin as the same as endogenous 13 
Gal-3. In addition, recombinant Gal-3 significantly increased the expression of 14 
N-cadherin and CD44 in either PC-3M cells or A549 cells, while could not regulate 15 
the expression of these two CAMs in the presence of ICG-001, suggesting that 16 
exogenous Gal-3 upregulated the expression of N-cadherin and CD44 in both A549 17 
cells and PC-3M cells through promoting β-catenin/TCF-mediating transcription. 18 
What’s more, A549 cells adhesion to HUVECs was inhibited by suppression of 19 
N-cadherin and CD44, increased after treatment with recombinant Gal-3 by 20 
upregulating the expression of these two CAMs, further indicating that exogenous 21 
Gal-3 promoted cancer cells adhesion to HUVECs by increasing the expression of 22 
N-cadherin and CD44 in the presence of β-catenin. 23 
In conclusion, exogenous as well as endogenous Gal-3 promotes cancer cells 24 
adhesion to vascular endothelial cells by increasing the expression of N-cadherin and 25 
CD44 via an increase of β-catenin nuclear accumulation. Moreover, the effect of 26 
endogenous Gal-3 on the metastasis of A549 cells with low expression of MUC1 was 27 
confirmed in vivo. This indicates a new molecular mechanism of Gal-3-mediated cell 28 
adhesion in cancer metastasis and may have therapeutic potential for developing new 29 
strategies to prevent metastasis.    30 
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Figure legends 1 
Figure 1. Effects of intracellular and extracellular Gal-3 on tumor cells adhesion to 2 
HUVECs. Tumor cells adhesion to HUVEC monolayer was assessed using DIO 3 
fluorescent-labelled tumor cells. Expression of Ga1-3 (A) and MUC1 (B) in HT-29, 4 
A549 or PC-3M cells was determined by Western blotting. C: MUC1 mRNA levels in 5 
HT-29, A549 and PC-3M cells were determined by qRT-PCR. D: Recombinant Gal-3 6 
could not affect the expression of MUC1 in A549 and PC-3M cells. E: siRNA Gal-3 7 
suppression decreased A549 cells adhesion to HUVECs. The adhesion of PC-3M cells 8 
(F) or A549 cells (G) to HUVECs was determined after treatment of the cells with 9 
different concentration of recombinant Gal-3 for 8 h. Data are presented as the means 10 
± S.E. from three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001, NS, not 11 
significant, when compared with blank group. 12 
 13 
Figure 2. Downregulation of Gal-3 expression decreased A549 cell adhesion to 14 
HUVECs through inhibition of nuclear accumulation of β-catenin. A: suppression of 15 
cell-associated Gal-3 significantly inhibited accumulation of β-catenin in nucleus. B: 16 
ICG-001 decreased A549 cell adhesion to HUVECs. C: ICG-001 abolished inhibition 17 
of A549 cell adhesion to HUVECs induced by suppression of cell-associated Gal-3. 18 
Data are presented as the means ± S.E. from three separate experiments. *P < 0.05, 19 
***P < 0.001, NS, not significant, vs. blank group. 20 
 21 
Figure 3. Downregulation of N-cadherin and CD44 expression induced by 22 
suppression of cell-associated Gal-3 was abolished by inhibition of β-catenin/TCF 23 
gene transcription. A: The expression of N-cadherin, CD44 in A549 cells was 24 
downregulated by siGal-3 treatment. B: High expression of N-cadherin showed in 25 
either HUVECs or A549 cells. C: ICG-001 decreased the expression of N-cadherin 26 
but not CD44. D: ICG-001 abolished the downregulation of N-cadherin and CD44 27 
induced by suppression of cell-associated Gal-3. Data are presented as the means ± 28 
S.E. from three separate experiments. *P < 0.05, **P < 0.01, vs. control group. 29 
 30 
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Figure 4. Exogenous Gal-3 increased nuclear accumulation of β-catenin via 1 
internalization in PC-3M cells. A: PC-3M cells were treated with 1 μg/ml Gal-3 for 2 2 
h. Gal-3 was visualized with an anti-galectin-3 antiboby (red), and the cell nucleus 3 
was visualized with Hoechst 33342 (bule). B: The expression of Gal-3, N-cadherin 4 
and CD44 in PC-3M cells after incubation with 0.5 μg/ml recombinant Gal-3 at 5 
different time points was assessed by Western blotting. C: After treatment with 0.5, 1 6 
μg/ml Gal-3 for 8 h, the expression of Gal-3 and β-catenin in cytoplasm and nucleus 7 
of PC-3M cells was assessed by Subcellular Structure of Cytoplasm and Cell Nucleus 8 
Extraction Kit and Western blotting. The band densities were quantified by Chemidoc 9 
XRS imaging system (Bio-Rad, Hercules, California, USA) and were normalized to 10 
β-actin. Data are presented as the means ± S.E. from three separate experiments. *P < 11 
0.05, **P < 0.01, ***P < 0.001, vs. control group. 12 
 13 
Figure 5. Exogenous Gal-3 increased nuclear accumulation of β-catenin via 14 
internalization in A549 cells. A: A549 cells were treated with 1 μg/ml Gal-3 for 2 h. 15 
Gal-3 was visualized with an anti-galectin-3 antiboby (red), and the cell nucleus was 16 
visualized with Hoechst 33342 (bule). B: After siRNA suppression of Gal-3, A549 17 
cells were incubated with or without 1 μg/ml Gal-3 for 8 h, and the expression of 18 
gal-3 and β-catenin in cytoplasm and nucleus of A549 cells was assessed by 19 
Subcellular Structure of Cytoplasm and Cell Nucleus Extraction Kit and Western 20 
blotting. C: After treatment with 1 μg/ml Gal-3 for 2 h, the expression of Gal-3 in 21 
cytoplasm and cytomembrane of A549 and PC-3M cells was assessed by Membrane 22 
and Cytosol Protein Extraction Kit and Western blotting. The band densities were 23 
quantified by Chemidoc XRS imaging system (Bio-Rad, Hercules, California, USA) 24 
and were normalized to β-actin. Data are presented as the means ± S.E. from three 25 
separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001, vs. control group. 26 
 27 
Figure 6. Effect of exogenous Gal-3 on A549 cell adhesion to HUVECs was affected 28 
by siGal-3 and ICG-001. A: Exogenous Gal-3 increases adhesion of A549 cells which 29 
was transfected with siGal-3. B: The increase of Gal-3-mediated A549 cell adhesion 30 
26 
 
to HUVECs was significantly inhibited by the presence of ICG-001. C: The increase 1 
of Gal-3-mediated PC-3M cell adhesion to HUVECs was significantly inhibited by 2 
the presence of ICG-001. Data are presented as the means ± S.E. from three separate 3 
experiments. **P < 0.01, ***P < 0.001, NS, not significant. 4 
 5 
Figure 7. Exogenous Gal-3 increased the expression of N-cadherin and CD44 in 6 
PC-3M and A549 cells by internalization. A and B: After 8 h treatment of the cells 7 
with recombination Gal-3 (0.5, 1 μg/ml) expression of N-cadherin and CD44 in 8 
PC-3M cells (A) and A549 cells (B) were both increased. C and D: The expression of 9 
N-cadherin, CD44 and Gal-3 were assessed after incubation of the Gal-3 suppressed 10 
A549 cells with or without 1 μg/ml Gal-3 for 8 h (C) or in the presence of 10 μmol/L 11 
ICG-001 (D). The band densities of these proteins were quantified by Chemidoc XRS 12 
imaging system (Bio-Rad, Hercules, California, USA) and normalized to β-actin. 13 
Data are presented as the means ± S.E. from three separate experiments. *P < 0.05, 14 
**P < 0.01, vs. control group. NS, not significant.  15 
 16 
Figure 8. Exogenous Gal-3 promoted tumor cell-HUVEC adhesion by upregulation of 17 
the expression of N-cadherin and CD44 in cells of N-cadherin and CD44 suppression. 18 
A and B: The effect of exogenous Gal-3 on A549 cell adhesion to HUVECs after 19 
siRNA suppression of N-cadherin (A) and CD44 (B). C: A549 cells were treated with 20 
1 μg/ml recombinant Gal-3 for 8 h after transfection of the cells with N-cadherin 21 
siRNA or CD44 siRNA. The expression of N-cadherin and CD44 were determined by 22 
Western blotting. Data are presented as the means ± S.E. from three separate 23 
experiments. *P < 0.05, **P < 0.01. 24 
 25 
Figure 9. Effect of cell-associated Gal-3 on the migration and invasion of A549 cells. 26 
Effects of cell-associated Gal-3 on the migration and invasion of A549 cells in the 27 
presence or absence of 10 μmol/L ICG-001 were determined using wound scratch 28 
assay (A) or transwell invasion assay (B). C: Effects of ICG-001 on the expression of 29 
MMP-2 and MMP-9 were evaluated by Western blotting. Data are presented as the 30 
27 
 
means ± S.E. from three separate experiments. **P < 0.01, ***P < 0.001, vs. control 1 
siRNA. 2 
Figure 10. Downregulation of Gal-3 inhibited pumonary metastasis of A549 cells in 3 
nude mice. A, B and C: A549-Luc cells which were transfected with siGal-3 or 4 
control siRNA were injected into nude mice via tail vein to observe lung metastasis in 5 
IVIS Imaging system at day 10, 20, 40. D. Macroscopic appearance of lungs at day 40 6 
after tumor cell injections. Arrows, metastatic foci. 7 
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